PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: ChromaDex, Inc.

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

ott Licenses Pteropure® Technology from Chromadex - Partnership announced for proprietary berry blend brings leaders in science and consumer products together (NYSE: COT; TSX: BCB) (OTCBB: CDXC)
ott Licenses Pteropure® Technology from Chromadex


NewswireToday - /newswire/ - Irvine, CA, United States, 2011/06/28 - Partnership announced for proprietary berry blend brings leaders in science and consumer products together (NYSE: COT; TSX: BCB) (OTCBB: CDXC).

Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


Cott Beverages, Inc., a subsidiary of Cott Corporation, the world’s largest private label beverage company, and ChromaDex Inc. announced today that the two companies have entered into a licensing and supply agreement for the joint development of a clinically-backed, proprietary ingredient blend to serve the food & beverage, nutraceutical, and cosmetic markets.

“This agreement provides Cott access to ChromaDex’s pTeroPure® platform and establishes a relationship with a science-based leader in the nutraceutical industry,” remarked Doug Lynch, VP Business Development of the Star PhytoNutrients division of Cott. “We are excited to partner with ChromaDex, a name synonymous with both quality and science, and license its technology as part of our commitment to offering novel, best-in-class ingredients to our customers.”

“For ChromaDex, this agreement represents a great opportunity to license our growing portfolio of intellectual property to a recognized market leader in the consumer goods industry,” ChromaDex President Bill Spengler commented. “Cott’s market presence, distribution strength, consumer experience, and commitment to products with enhanced functionality and health benefits make it an exceptional partner as we continue to commercialize our pipeline of technology.”

About Star PhytoNutrients
The Star PhytoNutrients division of Cott Beverages Inc., a subsidiary of Cott Corporation (, develops and markets value-added botanical, fruit, antioxidant and highly functional ingredients, specializing in juice concentrates, fruit powders, and fruit extracts for use in food, beverages, nutraceuticals and cosmeceuticals. With a full line of ingredients derived from cranberries, the number one botanical ingredient in North America, Star PhytoNutrients has developed proprietary technologies for enhanced product functionality. For more information, please contact Douglas Lynch or Richard Star at 716-366-6100, or visit the website.

About ChromaDex
ChromaDex ( is an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, cosmetic and pharmaceutical industries. The company has an impressive pipeline of new ingredients, including its pTeroPure® pterostilbene for which it has worldwide, exclusive patent rights.

About pTeroPure®
pTeroPure® ( is an ultra-pure formulation of pterostilbene, a compound found in blueberries and demonstrated to have multiple health benefits. pTeroPure® was recently named the 2010 North American Most Promising Ingredient of the Year by the prestigious independent research company, Frost & Sullivan. The first human clinical research study on pTeroPure is being conducted at the University of Mississippi Medical Center to evaluate the compound in patients with lipid (cholesterol) disorders. pTeroPure® is incorporated in several nutraceutical brands available at retailers nationwide. Capitalizing on the diverse potential applications of the product, ChromaDex is also developing pTeroPure for the skincare and pharmaceutical markets. For more information about pTeroPure, visit the webstie or call 949-600-9694.

ChromaDex Forward-Looking Statements
Any statements that are not historical facts contained in this release are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to product and customer demand, market acceptance of our products, the effect of economic conditions both nationally and internationally, ability to protect our intellectual property rights, impact of any litigation or infringement actions brought against us, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, the ability to complete transactions, and other factors discussed from time to time in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.

ChromaDex Investor Inquiries:
Liviakis Financial Communications, Inc.
John M. Liviakis, President
P: 415-389-4670 / E: John[.]

Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


Written by / Agency / Source: ChromaDex, Inc.


Availability: All Regions (Including Int'l)


Traffic Booster: [/] Quick Newswire Today Visibility Checker


Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

# # #

  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!

ott Licenses Pteropure® Technology from Chromadex

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Publisher Contact: Carolyn Hawley - 
619-849-5375 carolyn[.]
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any ChromaDex, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Read Latest Articles From ChromaDex, Inc. / Company Profile

Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe
BTG and Mirada Medical Announce CE Mark Certification for Simplicit90Y Dosimetry Software in Europe
FDA Grants Priority Review to Genentech’s Lucentis® (Ranibizumab Injection) Supplemental Biologics License Application
Genentech’s TECENTRIQ® (Atezolizumab) Shows Significant Survival Advantage Compared to Chemotherapy
Greenphire Continues Commitment to Clinical Research Site Sustainability and Innovation at Global Site Solutions Summit
Frost & Sullivan Highlights argenx for Enhancing the Therapeutic Qualities of Human Antibodies with its Proprietary Antibody Discovery Platform, SIMPL
FDA Grants Breakthrough Therapy Designation for Genentech’s Actemra® (Tocilizumab) in Giant Cell Arteritis, a Form of Vasculitis
MDxHealth Announces Agreement with SouthGenetics for Distribution of SelectMDx in Central/South America
BD and Apax Partners Announce Closing of Joint Venture to Launch Global Respiratory Business
Exosome Diagnostics Enters Agreement with Amgen
Sartorius Stedim Biotech Launches Two Single-use Sartocon® Loop Assemblies with Integrated Polyethersulfone (PESU) Membrane
BD Expands Efforts to Combat Antimicrobial Resistance with New Automated ID/AST System

Boost Your Social Network
& Crowdfunding Campaigns

NewswireToday Celebrates 10 Years in Business


Visit  Intrinsic Executive Search Ltd

Visit  MagLar, Inc.

  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (